UK markets closed
NIKKEI 225
38,179.46 -49.65 (-0.13%) HANG SENG
19,115.06 +151.38 (+0.80%) CRUDE OIL
78.74 +0.48 (+0.61%) GOLD FUTURES
2,340.80 -34.20 (-1.44%) DOW
39,451.22 -61.62 (-0.16%) Bitcoin GBP
50,044.10 +1,139.23 (+2.33%)
Inozyme Pharma, Inc. (INZY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 01:32PM EDT. Market open.
| Previous close | 4.5400 |
| Open | 4.5600 |
| Bid | 4.5100 x 200 |
| Ask | 4.5400 x 100 |
| Day's range | 4.4999 - 4.7100 |
| 52-week range | 2.6890 - 7.7950 |
| Volume | |
| Avg. volume | 692,727 |
| Market cap | 280.515M |
| Beta (5Y monthly) | 1.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)
Key Insights Given the large stake in the stock by institutions, Inozyme Pharma's stock price might be vulnerable to...
- Zacks
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.
private equity firms who own 39% along with institutions invested in Inozyme Pharma, Inc. (NASDAQ:INZY) saw increase in their holdings value last week
Key Insights The considerable ownership by private equity firms in Inozyme Pharma indicates that they collectively have...
© 2024 Yahoo. All rights reserved.